---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-000073"
form_type: "8-K"
ticker: "ZEOX"
cik: "0001557376"
company_name: "Zeo ScientifiX, Inc."
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:21:24.140393+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zeo partners to commercialize Cytora's oral mucosal stem cell therapy under Florida law

## Summary
- Zeo gets exclusive U.S. commercial rights to Cytora's allogeneic oral mucosal stem cell therapy (hOMSC200).
- Initial commercialization under Florida SB 1768 for diabetic foot ulcers; estimated 125,000 new patients annually in Florida alone.
- Phase 1/2a trial showed favorable safety and statistically significant complete wound closure in 27-month average-open ulcers.
- Made Scientific handles GMP manufacturing at Princeton, NJ; Zeo provides market access, distribution, and clinical site management.
- Partnership also plans U.S. FDA Phase 2b trial aiming for approved license.

## SEC filing metadata
- accession: 0001829126-26-000073
- form_type: 8-K
- ticker: ZEOX
- cik: 0001557376
- company_name: Zeo ScientifiX, Inc.
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557376/000182912626000073/0001829126-26-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557376/000182912626000073/zeoscientifix_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-000073
- JSON: https://secwatch.observer/filing/0001829126-26-000073.json
- Plain text: https://secwatch.observer/filing/0001829126-26-000073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.